Tonix Pharmaceuticals Holding (TNXP) Total Current Liabilities (2010 - 2026)

Tonix Pharmaceuticals Holding's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $29.6 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 144.09% year-over-year to $29.6 million in Q1 2026; TTM through Mar 2026 was $29.6 million, a 144.09% increase from a year earlier, with the FY2025 full-year figure at $30.8 million, up 68.44% from the prior year.
• Total Current Liabilities eased to $29.6 million in Q1 2026 per TNXP's latest filing, from $30.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $30.8 million in Q4 2025 and bottomed at $12.1 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $18.3 million (2024), against an average of $18.8 million.
• Across the five-year window, Total Current Liabilities soared 154.71% in 2022 and slumped 40.69% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $18.2 million in 2022, then gained by 3.87% to $18.9 million in 2023, then slipped by 3.06% to $18.3 million in 2024, then soared by 68.44% to $30.8 million in 2025, then retreated by 3.86% to $29.6 million in 2026.
• Per Business Quant, the three latest TNXP Total Current Liabilities figures stand at $29.6 million (Q1 2026), $30.8 million (Q4 2025), and $21.0 million (Q3 2025).